Thrombomodulin's lectin-like domain reduces myocardial damage by interfering with HMGB1-mediated TLR2 signalling

Cardiovascular Research

Volumn 101, Issue 3, 2014, Pages 400-410

  Herzog, Christine ^a   Lorenz, Anika ^a   Gillmann, Hans Jörg ^a   Chowdhury, Arpita ^a   Larmann, Jan ^a   Harendza, Thomas ^a   Echtermeyer, Frank ^a   Müller, Martin ^a   Schmitz, Martina ^b   Stypmann, Jörg ^b   Seidler, Daniela G ^b   Damm, Martin ^c   Stehr, Sebastian N ^d   Koch, Thea ^c   Wollert, Kai C ^a   Conway, Edward M ^e   Theilmeier, Gregor ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^c UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^d JENA UNIVERSITY HOSPITAL   (Germany)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Apoptosis; High mobility group box 1; Myocardial ischaemia; Thrombomodulin; Toll like receptors

Indexed keywords

APOPTOSIS; HIGH-MOBILITY GROUP BOX 1; MYOCARDIAL ISCHAEMIA; THROMBOMODULIN; TOLL-LIKE RECEPTORS;

ANIMALS; APOPTOSIS; CELLS, CULTURED; HMGB1 PROTEIN; INFLAMMATION; MICE; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; MYOCYTES, CARDIAC; SIGNAL TRANSDUCTION; THROMBOMODULIN; TOLL-LIKE RECEPTOR 2;

EID: 84894523888     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvt275     Document Type: Article

References (34)

1. BlankesteijnWM, Creemers E, Lutgens E, Cleutjens JP, Daemen MJ, Smits JF. Dynamics of cardiac wound healing following myocardial infarction: observations in genetically altered mice. Acta Physiol Scand 2001;173:75-82.
2. Frassdorf J, De Hert S, Schlack W. Anaesthesia and myocardial ischaemia/reperfusion injury. Br J Anaesth 2009;103:89-98.
3. Heymans S, Luttun A, Nuyens D, Theilmeier G, Creemers E, Moons L et al. Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure. NatMed 1999;5:1135-1142.
4. Esmon CT. Thrombomodulin as a model of molecular mechanisms that modulate protease specificity and function at the vessel surface. FASEB J 1995;9:946-955.
5. Conway EM, Van deWouwer M, Pollefeyt S, Jurk K, Van Aken H, De Vriese A et al. The lectin-like domain of thrombomodulin confers protection from neutrophil-mediated tissue damage by suppressing adhesion molecule expression via nuclear factor kappaB and mitogen-activated protein kinase pathways. J Exp Med 2002;196:565-577.
6. Van deWouwer M, Plaisance S, De Vriese A, Waelkens E, Collen D, Persson J et al. The lectin-like domain of thrombomodulin interferes with complement activation and protects against arthritis. J Thromb Haemost 2006;4:1813-1824.
7. Geudens N, Van de Wouwer M, Vanaudenaerde BM, Vos R, Van De Wauwer C, Verleden GM et al. The lectin-like domain of thrombomodulin protects against ischaemia-reperfusion lung injury. Eur Respir J 2008;32:862-870.
8. Abeyama K, Stern DM, Ito Y, Kawahara K, Yoshimoto Y, TanakaMet al. The N-terminal domain of thrombomodulin sequesters high-mobility group-B1 protein, a novel antiinflammatory mechanism. J Clin Invest 2005;115:1267-1274.
9. Bustin M. Regulation of DNA-dependent activities by the functional motifs of the high-mobility-group chromosomal proteins. Mol Cell Biol 1999;19:5237-5246.
10. Lotze MT, Tracey KJ. High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol 2005;5:331-342.
11. Scaffidi P, Misteli T, Bianchi ME. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 2002;418:191-195.
12. Muller S, Ronfani L, Bianchi ME. Regulated expression and subcellular localization of HMGB1, a chromatin protein with a cytokine function. J Intern Med 2004;255:332-343.
13. BellCW, JiangW, Reich CF III, Pisetsky DS. The extracellular release of HMGB1 during apoptotic cell death. Am J Physiol Cell Physiol 2006;291:C1318-C1325.
14. Gauley J, Pisetsky DS. The translocation of HMGB1 during cell activation and cell death. Autoimmunity 2009;42:299-301.
15. Kohno T, Anzai T, Naito K, Miyasho T, Okamoto M, YokotaHet al. Role of high-mobility group box 1 protein in post-infarction healing process and left ventricular remodelling. Cardiovasc Res 2009;81:565-573.
16. Kitahara T, Takeishi Y, Harada M, Niizeki T, Suzuki S, Sasaki T et al. High-mobility group box 1 restores cardiac function after myocardial infarction in transgenic mice. Cardiovasc Res 2008;80:40-46.
17. Limana F, Germani A, Zacheo A, Kajstura J, Di Carlo A, Borsellino G et al. Exogenous high-mobility group box 1 protein induces myocardial regeneration after infarction via enhanced cardiac C-kit+ cell proliferation and differentiation. Circ Res 2005;97: e73-e83.
18. Andrassy M, Volz HC, Igwe JC, Funke B, Eichberger SN, KayaZ et al. High-mobility group box-1 in ischemia-reperfusion injury of the heart. Circulation 2008;117:3216-3226.
19. Takahashi K, Fukushima S, Yamahara K, YashiroK, ShintaniY, Coppen SR et al. Modulated inflammation by injection of high-mobility group box 1 recovers post-infarction chronically failing heart. Circulation 2008;118:S106-S114.
20. Theilmeier G, Schmidt C, Herrmann J, Keul P, Schafers M, Herrgott I et al. High-density lipoproteins and their constituent, sphingosine-1-phosphate, directly protect the heart against ischemia/reperfusion injury in vivo via the S1P3 lysophospholipid receptor. Circulation 2006;114:1403-1409.
21. TodaroGJ, GreenH. Quantitative studies of the growth of mouse embryo cells in culture and their development into established lines. J Cell Biol 1963;17:299-313.
22. Fiedler B, Feil R, Hofmann F, Willenbockel C, Drexler H, Smolenski A et al. cGMP-dependent protein kinase type I inhibits TAB1-p38 mitogen-activated protein kinase apoptosis signaling in cardiac myocytes. J Biol Chem 2006;281:32831-32840.
23. Louch WE, Sheehan KA, Wolska BM. Methods in cardiomyocyte isolation, culture, and gene transfer. J Mol Cell Cardiol 2011;51:288-298.
24. Claycomb WC, Lanson NA Jr, Stallworth BS, Egeland DB, Delcarpio JB, Bahinski A et al. HL-1 cells: a cardiac muscle cell line that contracts and retains phenotypic characteristics of the adult cardiomyocyte. Proc Natl Acad Sci US 1998;95:2979-2984.
25. Maeda T, Balakrishnan K, Mehdi SQ. A simple and rapid method for the preparation of plasma membranes. Biochim Biophys Acta 1983;731:115-120.
26. Suzuki K, Bose P, Leong-Quong RY, Fujita DJ, Riabowol K. REAP: a two minute cell fractionation method. BMC Res Notes 2010;3:294.
27. Metzler B, Hammerer-Lercher A, Jehle J, Dietrich H, Pachinger O, Xu Q et al. Plasma cardiac troponin T closely correlates with infarct size in a mouse model of acute myocardial infarction. Clin Chim Acta 2002;325:87-90.
28. Frangogiannis NG. The mechanistic basis of infarct healing. Antioxid Redox Signal 2006;8: 1907-1939.
29. Limana F, Esposito G, D'Arcangelo D, Di Carlo A, Romani S, Melillo G et al. HMGB1 attenuates cardiac remodelling in the failing heart via enhanced cardiac regeneration and miR-206-mediated inhibition of TIMP-3. PLoS One 2011;6:e19845.
30. Ishii H, MajerusPW. Thrombomodulin is present in human plasma and urine. J Clin Invest 1985;76:2178-2181.
31. Wang L, Bastarache JA, Wickersham N, Fang X, Matthay MA, Ware LB. Novel role of the human alveolar epithelium in regulating intra-alveolar coagulation. Am J Respir Cell Mol Biol 2007;36:497-503.
32. Wu HL, Lin CI, Huang YL, Chen PS, Kuo CH, Chen MS et al. Lysophosphatidic acid stimulates thrombomodulin lectin-like domain shedding in human endothelial cells. Biochem Biophys Res Commun 2008;367:162-168.
33. Nagato M, Okamoto K, Abe Y, Higure A, Yamaguchi K. Recombinant human soluble thrombomodulin decreases the plasma high-mobility group box-1 protein levels, whereas improving the acute liver injury and survival rates in experimental endotoxemia. Crit Care Med 2009;37:2181-2186.
34. Hagiwara S, Iwasaka H, Goto K, Ochi Y, Mizunaga S, Saikawa Tet al. Recombinant thrombomodulin prevents heat stroke by inhibition of high mobility group box 1 protein in sera of rats. Shock 2010;34:402-406.